• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:17:19 PM ET
    $CFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CFRX alert in real time by email
    SC 13G/A 1 contrafect_13gax2x21.htm CONTRAFECT SC 13G/A Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)*


    ContraFect Corporation
    (Name of Issuer)


    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    212326300
    (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule
    is filed:

    |_| Rule 13d-1(b)
    |X| Rule 13d-1(c)
    |_| Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. 212326300
    1.
    Names of Reporting Persons. PFIZER INC.
    I.R.S. Identification Nos. of Above Persons (entities only) 13-5315170
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    (b)
    3.
    SEC Use Only
    4.
    Citizenship or Place of Organization
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5.
    Sole Voting Power: 1,785,267 shares of Common Stock, $0.0001 par value per share (“Common Stock”)
    6.
    Shared Voting Power: -0-
    7.
    Sole Dispositive Power: 1,785,267 shares of Common Stock
    8.
    Shared Dispositive Power: -0-
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person: 1,785,267 shares of Common Stock are beneficially owned by Pfizer Inc.
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
    (See Instructions)
    11.
    Percent of Class Represented by Amount in Row (9): 6.4% (1)
    12.
    Type of Reporting Person (See Instructions): CO

    ____________________
    1Based on 27,810,082 shares of Common Stock outstanding as of November 6, 2020, as reported in the issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2020 (“Form 10-Q”).




    ITEM 1.
    (A) NAME OF ISSUER: ContraFect Corporation

    (B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE: 28 Wells Avenue, 3
    rd Floor, Yonkers, New York 10701

    ITEM 2.
    (A) NAME OF PERSONS FILING:
    Pfizer Inc. (“Pfizer”)

    (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE:
    235 E. 42nd Street, New York, NY 10017

    (C) CITIZENSHIP:
    Delaware, U.S.A.

    (D) TITLE OF CLASS OF SECURITIES:
    Common Stock

    (E) CUSIP NUMBER:
    212326300

    ITEM 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.
    (a)
    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
     ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
     ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
    (f )
     ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)
    ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14)



    of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)
     ☐ A non-US institution, in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)
    ☐ Group, in accordance with §230.405 240.13d-1(b)(1)(ii)(K).

    If filing as a non-US institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.  
    ITEM 4. OWNERSHIP.
    See rows 5 through 11 of the cover pages.
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
    Not applicable.  

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
    Not applicable.  

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
    Not applicable.  

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
    Not applicable.  

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP
    Not applicable.  

    ITEM 10. CERTIFICATION
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.










     Signature
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021


    PFIZER INC.

    By: /s/ Susan Grant
    Name: Susan Grant
    Title: Assistant Secretary


    Get the next $CFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFRX

    DatePrice TargetRatingAnalyst
    7/14/2022$1.00Outperform → Mkt Perform
    SVB Leerink
    7/14/2022$15.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    2/16/2022$14.00 → $9.00Outperform
    SVB Leerink
    2/2/2022$6.50Speculative Buy → Buy
    WBB Securities
    9/9/2021$14.00Outperform
    SVB Leerink
    More analyst ratings

    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

      YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of

      10/16/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

      YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap

      9/19/23 8:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

      YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h

      9/18/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Messinger Michael

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      2/16/23 8:09:36 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Barlow Jane F

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:12:43 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sucoff Cary

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:03:32 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer

      Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress

      8/9/21 8:00:00 AM ET
      $CFRX
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

      YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i

      6/17/21 7:31:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      2/14/24 2:24:05 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ContraFect Corporation

      SC 13G - CONTRAFECT Corp (0001478069) (Subject)

      2/14/23 12:22:09 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      9/9/22 11:03:32 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ContraFect downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00

      7/14/22 7:16:02 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously

      7/14/22 7:15:41 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on ContraFect with a new price target

      SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously

      2/16/22 5:18:49 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ContraFect Corporation

      25-NSE - CONTRAFECT Corp (0001478069) (Subject)

      12/27/23 9:01:56 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - CONTRAFECT Corp (0001478069) (Filer)

      11/15/23 4:41:00 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ContraFect Corporation

      10-Q - CONTRAFECT Corp (0001478069) (Filer)

      11/14/23 4:00:30 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care